National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov

Clinical Trials by Cancer Site

Breast Cancer

Breast cancer is the most commonly diagnosed type of cancer in women. It is estimated that in 2008, there will be 182,460 new cases of invasive breast cancer in women and 1,990 cases in men. The risk factors for breast cancer include age, high breast tissue density, confirmed hyperplasia, long menstrual cycles, use of oral contraceptives, having first child after the age of 30, never having children, inherited genetic mutations (BRCA 1 and BRCA 2), personal or family history of breast cancer, and having received high-dose radiation therapy to the chest for medical treatment.

Treatment options for breast cancer may vary depending on tumor size, stage of the disease, whether the cancer is newly diagnosed or recurrent/refractory, other medical conditions, and the patient's treatment preference, and should be discussed with the patient's physician.

Breast Cancer Clinical Trials

The Center for Cancer Research (CCR), NCI's largest division doing research on campus, conducts breast clinical trials at the NIH Clinical Center in Bethesda, Md. NCI accepts referrals to breast clinical trials conducted in Bethesda, Md., through its Clinical Trials Referral Office (formerly the Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937).

NCI is currently conducting the following trials for patients with breast cancer. Click on the trials below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact the principal investigators and their staff directly.


  
Trial and Protocol Number
Breast Cancer
Phase II
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Patients With Metastatic Breast Cancer
NCI-05-C-0229

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I/II
A Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion
NCI-03-C-0040

Principal Investigator:Referral Contact:
Claude SportésMike Krumlauf
301-435-5280301-594-2056
krumlaum@mail.nih.gov
Phase I
A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA 1/2 Mutation Carriers and Familial Breast and Ovarian Cancer
NCI-08-C-0092

Principal Investigator:Referral Contact:
Elise C. KohnLaura D. Otten
301-402-2726301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I Trial of T Cell Exchange With Th2/Tc2 Cells for Allogenic Stem Cell Transplantation After Reduced Intensity Conditioning for Metastatic Breast Cancer
NCI-04-C-0131

Principal Investigator:Referral Contact:
Michael BishopMike Krumlauf
301-435-2764301-594-2056
krumlaum@mail.nih.gov
No Phase
Pilot Trial to Identify and Characterize Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer
NCI-07-C-0123

Principal Investigator:Referral Contact:
Jennifer Eng-WongGuinevere Chun
301-496-5320301-451-7868
gchun@mail.nih.gov
Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile
NCI-02-C-0077

Principal Investigator:Referral Contact:
David N. Danforth
301-496-1533



  
Trial and Protocol Number
Ovarian Cancer
No Phase
Clinical, Genetic, Behavioral, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
NCI-02-C-0212

Principal Investigator:Referral Contact:
Phuong MaiStephanie Steinbart
301-496-99281-800-518-8474
(Toll Free)



  
Trial and Protocol Number
Solid Tumor
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses HER-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-HER-2 Gene Engineered Lymphocytes
NCI-09-C-0041

Principal Investigator:Referral Contact:
Steven A. RosenbergLinda Williams
1-866-820-4505
(Toll Free)
1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov


  
Trial and Protocol Number
Solid Tumor (Adult)
Phase I
A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
NCI-06-C-0221

Principal Investigator:Referral Contact:
James DoroshowJanelle Bingham
301-496-4291301-435-2715
jbingham@mail.nih.gov
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors
NCI-00-C-0121

Principal Investigator:Referral Contact:
John E. JanikGuinevere Chun
301-402-2913301-451-7868
gchun@mail.nih.gov
Phase 0
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer
NCI-07-C-0101

Principal Investigator:Referral Contact:
Peter ChoykeYolanda McKinney
301-451-4220301-443-1718
ymckinney@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov National Cancer Institute Clinical Trials at NIH - Be part of the cure